Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast

Eli Lilly reported second-quarter gross of $23.0 cardinal connected Wednesday, a 48% summation from a twelvemonth earlier, and lifted its full-year gross people to a scope of $85 cardinal to $87 billion, compared with the anterior forecast of $82 cardinal to $85 billion.

Demand for diabetes cause Mounjaro and value nonaccomplishment cause Zepbound drove the results. Mounjaro gross roseate 91% to $9.9 cardinal for the quarter, including $4.8 cardinal successful U.S. income and $5.2 cardinal internationally. Zepbound generated $4.9 cardinal successful U.S. revenue, a 44% year-over-year gain, with beardown medicine request much than making up for a diminution successful nett prices.

On an adjusted basis, Lilly earned $8.38 per stock successful the 2nd quarter, handily clearing expert expectations of $6.01; gross of astir $23 cardinal besides topped the $20.73 cardinal statement estimate, according to CNBC.

On a reported basis, nett income came successful astatine $7.1 billion, oregon $7.94 per share, a astir 25% summation from $5.7 billion, oregon $6.29 per share, successful the aforesaid play past year. Reported and adjusted net per stock each included $3.03 successful charges tied to acquired in-process probe and improvement from woody enactment successful the quarter.

Lilly's revised full-year adjusted net outlook of $35.50 to $36.50 per stock holds the level dependable portion trimming the ceiling from the erstwhile $35.50 to $37.00 range; the institution said a $2.78 per stock summation successful halfway concern show was much than wiped retired by $3.03 per stock successful acquisition-related charges. Lilly said it besides committed an further $4.5 cardinal to grow Indiana manufacturing sites.

International gross reached $8.6 billion, an 80% increase, lifted by a 113% leap successful measurement adjacent arsenic a 36% terms diminution weighed connected results — a driblet tied mostly to Mounjaro's inclusion connected China's nationalist reimbursement formulary for Type 2 diabetes. Domestic gross reached $14.4 billion, a 33% summation implicit the prior-year period.

Lilly besides reported its archetypal quarterly gross figures for Foundayo, its recently approved oral value nonaccomplishment and diabetes pill. The pill brought successful $98 cardinal for the quarter, falling somewhat abbreviated of the astir $103 cardinal that analysts had anticipated, according to CNBC.

The beardown results travel arsenic Lilly has pursued a drawstring of acquisitions. During the 2nd quarter, the institution completed deals for Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics. After the 4th closed, Lilly agreed to get AtaiBeckley, a clinical-stage institution processing psychedelic-based treatments for intelligence wellness conditions including treatment-resistant depression, for astir $2.8 cardinal upfront. Lilly besides announced 3 further acquisitions to physique an infectious illness portfolio, the institution said.